Success of Treatment Modalities for Labial Fusion: A Retrospective Evaluation of Topical and Surgical Treatments

2009 ◽  
Vol 22 (4) ◽  
pp. 247-250 ◽  
Author(s):  
Lazarus Mayoglou ◽  
Lori Dulabon ◽  
Nieves Martin-Alguacil ◽  
Donald Pfaff ◽  
Justine Schober
Keyword(s):  
Treatment Modalities ◽  
Retrospective Evaluation ◽  
Labial Fusion ◽  
Surgical Treatments ◽  
Success Of Treatment

scholarly journals Flexible Video-Endsocopic Injection Sclerotherapy for Second and Third Degree Internal Hemorrhoids

2011 ◽  
Vol 02 (01) ◽  
pp. 001-005 ◽  
Author(s):  
Sandeep Nijhawan ◽  
Gaurav Gupta ◽  
Anil Sharma ◽  
Amit Mathur ◽  
Bharat Sapra ◽  
...  
Keyword(s):  
Injection Sclerotherapy ◽  
Endoscopic Sclerotherapy ◽  
Efficacy And Safety ◽  
Rectal Pain ◽  
Field Of Vision ◽  
Internal Hemorrhoids ◽  
Grade Ii ◽  
Surgical Treatments ◽  
Success Of Treatment ◽  
Grade Iii

ABSTRACT Background and objectives: Bleeding from hemorrhoids is the commonest cause of rectal bleeding in adults. Injection sclerotherapy of internal hemorrhoids is one of the non-surgical treatments, and is simple, safe and feasible. Conventionally sclerotherapy is performed with rigid proctoscope which has limitations of maneuverability, narrower field of vision and documentation compared to flexible videoendoscope. Therefore, we assessed the efficacy and safety of video-colonoscopic sclerotherapy for bleeding internal hemorrhides. Methods: Seventy-nine patients of bleeding internal hemorrhoids were subjected to colonoscopic sclerotherapy using 1.5% polidocanol in retroflexed or forward viewing positions. Success of treatment was defined as cessation of bleeding for six weeks. Patients were observed for complications and were followed up regularly for 3 months. Results: A total of 79 evaluable patients, 61 had grade II and 18 had grade III hemorrhoids. There was no statistically significant differences in achieving excellent or good results for control of bleeding between patients with grade II and grade III hemorrhoids (100% vs 94,5%; p>0.05). The number of sessions of sclerotherapy required were significantly more in grade II than grade III hemorrhoids (1.1 ± 0.3 vs 1.3 ± 0.7; p = 0.04). No significant complications were noted except for bloating in ten patients (12.6 %) and rectal pain in 6 (7.6%) patients. Median time taken for the procedure was 30 minutes. Conclusions: Video-endoscopic sclerotherapy is safe, well-tolerated and effective treatment for bleeding internal hemorrhoids.(J Dig Endosc 2011;2(1):1-5)

scholarly journals Novel Surgical Treatments for Benign Prostatic Hyperplasia

2019 ◽  
Vol 2 (1) ◽  
pp. e17-e23
Author(s):  
Blessing Dhliwayo ◽  
Saheel Mukhtar
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Gold Standard ◽  
Lower Urinary Tract ◽  
Minimal Invasive ◽  
Prostatic Hyperplasia ◽  
Treatment Modalities ◽  
Elderly Men ◽  
Urinary Tract Symptoms ◽  
Surgical Treatments ◽  
Lower Urinary

Transurethral resection of the prostate (TURP) has been the gold standard for the treatment of elderly men with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). However, over the last few years, advances in surgical treatment have led to the development of other treatment modalities. These innovations include convective WAter Vapor Energy (WAVE; Rezum System), prostatic urethral lift (PUL; UroLift System), Prostate Artery Embolisation (PAE) and Aquablation (AQUABEAM System). This review provides an update on these current minimal invasive surgical treatments. The evidence of their safety, tolerability and efficacy in clinical practice is reviewed.

Retrospective Evaluation of Surgical Treatments for Slipped Capital Femoral Epiphysis

2007 ◽  
pp. 3-8
Author(s):  
Hideki Fujii ◽  
Takuya Otani ◽  
Seijin Hayashi ◽  
Yasuhiko Kawaguchi ◽  
Hideaki Tamegai ◽  
...  
Keyword(s):  
Slipped Capital Femoral Epiphysis ◽  
Retrospective Evaluation ◽  
Surgical Treatments

Esophageal Resection for End-Stage Achalasia

2018 ◽  
Vol 84 (4) ◽  
pp. 506-511 ◽  
Author(s):  
Alberto Aiolfi ◽  
Emanuele Asti ◽  
Gianluca Bonitta ◽  
Stefano Siboni ◽  
Luigi Bonavina
Keyword(s):  
Balloon Dilation ◽  
Esophageal Resection ◽  
Treatment Modalities ◽  
Morbidity Rate ◽  
Safe Alternative ◽  
Thoracoscopic Approach ◽  
Long Term Follow Up ◽  
End Stage ◽  
Surgical Treatments

Achalasia is a rare disease characterized by impaired lower esophageal sphincter relaxation loss and of peristalsis in the esophageal body. Endoscopic balloon dilation and laparoscopic surgical myotomy have been established as initial treatment modalities. Indications and outcomes of esophagectomy in the management of end-stage achalasia are less defined. A literature search was conducted to identify all reports on esophagectomy for end-stage achalasia between 1987 and 2017. MEDLINE, Embase, and Cochrane databases were consulted matching the terms “achalasia,” “end-stage achalasia,” “esophagectomy,” and “esophageal resection.” Seventeen articles met the inclusion criteria and 1422 patients were included in this narrative review. Most of the patients had previous multiple endoscopic and/or surgical treatments. Esophagectomy was performed through a transthoracic (74%) or a transhiatal (26%) approach. A thoracoscopic approach was used in a minority of patients and seemed to be safe and effective. In 95 per cent of patients, the stomach was used as an esophageal substitute. The mean postoperative morbidity rate was 27.1 per cent and the mortality rate 2.1 per cent. Symptom resolution was reported in 75 to 100 per cent of patients over a mean follow-up of 43 months. Only five series including 195 patients assessed the long-term follow-up (>5 years) after reconstruction with gastric or colon conduits, and the results seem similar. Esophagectomy for end-stage achalasia is safe and effective in tertiary referral centers. A thoracoscopic approach is a feasible and safe alternative to thoracotomy and may replace the transhiatal route in the future.

scholarly journals Gene Therapy for Parkinson's Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Rachel Denyer ◽  
Michael R. Douglas
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
Symptomatic Relief ◽  
Disease Process ◽  
Treatment Modalities ◽  
Theoretical Approaches ◽  
Novel Approaches ◽  
Surgical Treatments

Current pharmacological and surgical treatments for Parkinson's disease offer symptomatic improvements to those suffering from this incurable degenerative neurological disorder, but none of these has convincingly shown effects on disease progression. Novel approaches based on gene therapy have several potential advantages over conventional treatment modalities. These could be used to provide more consistent dopamine supplementation, potentially providing superior symptomatic relief with fewer side effects. More radically, gene therapy could be used to correct the imbalances in basal ganglia circuitry associated with the symptoms of Parkinson's disease, or to preserve or restore dopaminergic neurons lost during the disease process itself. The latter neuroprotective approach is the most exciting, as it could theoretically be disease modifying rather than simply symptom alleviating. Gene therapy agents using these approaches are currently making the transition from the laboratory to the bedside. This paper summarises the theoretical approaches to gene therapy for Parkinson's disease and the findings of clinical trials in this rapidly changing field.

Simulation of Flow and Structural Dynamics in Human Upper Airways

2010 ◽  
Author(s):  
Goutham Mylavarapu ◽  
Ephraim Gutmark ◽  
Mihai Mihaescu ◽  
Shanmugam Murugappan
Keyword(s):  
Cardiovascular Health ◽  
Upper Airway ◽  
Diagnostic Methods ◽  
Treatment Modalities ◽  
Respiratory Disorder ◽  
Upper Airways ◽  
Obstructive Sleep ◽  
High Prevalence ◽  
Important Health ◽  
Surgical Treatments

Obstructive Sleep Apnea and Hypo Apnea Syndrome (OSAHS) is a respiratory disorder characterized by repeated episodes of partial or complete airway obstruction. OSAHS is also associated with decreased quality of life, decreased cardiovascular health, day-time sleepiness, and increased transportation accidents. Its high prevalence with as much as 4% of American population suffering from OSAHS also makes it an important health care issue[1]. Existing surgical treatments suffer from a moderate to high successful failure rates. Broader research on this respiratory disorder for a better understanding of the pathophysiology of human upper airway, to develop better diagnostic methods and treatment modalities is very much needed.

scholarly journals Operative Treatment for Osteochondral Lesions of the Talus

Cartilage ◽  
2016 ◽  
Vol 8 (1) ◽  
pp. 42-49 ◽  
Author(s):  
Youichi Yasui ◽  
Adi Wollstein ◽  
Christopher D. Murawski ◽  
John G. Kennedy
Keyword(s):  
Bone Marrow ◽  
Clinical Outcomes ◽  
Basic Science ◽  
Clinical Evidence ◽  
Surgical Techniques ◽  
Biologic Agents ◽  
Treatment Modalities ◽  
Patient Specific ◽  
Osteochondral Lesions ◽  
Surgical Treatments

Objective Numerous basic science articles have published evidence supporting the use of biologic augmentation in the treatment of osteochondral lesions of the talus (OLT). However, a comprehensive evaluation of the clinical outcomes of those treatment modalities in OLT has yet to be published. The purpose of this review is to provide an evidence-based overview of clinical outcomes following biologic augmentation to surgical treatments for OLT. Design A comprehensive literature review was performed. Two commonly used surgical techniques for the treatment of OLT—bone marrow stimulation and osteochondral autograft transfer—are first introduced. The review describes the operative indications, step-by- step operative procedure, clinical outcomes, and concerns associated with each treatment. A review of the currently published basic science and clinical evidence on biologic augmentation in the surgical treatments for OLT, including platelet-rich plasma, concentrated bone marrow aspirate, and scaffold-based therapy follows. Results Biologic agents and scaffold-based therapies appear to be promising agents, capable of improving both clinical and radiological outcomes in OLT. Nevertheless, variable production methods of these biologic augmentations confound the interpretation of clinical outcomes of cases treated with these agents. Conclusions Current clinical evidence supports the use of biologic agents in OLT cases. Nonetheless, well-designed clinical trials with patient-specific, validated and objective outcome measurements are warranted to develop standardized clinical guidelines for the use of biologic augmentation for the treatment of OLT in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document